X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Stempeucel® has been developed by Stempeutics and is the first allogeneic cell therapy product to be approved for commercial use in India and the first stem cell product to be approved globally for CLI treatment. Cipla will market and distribute in Stempeucel® India.
Lead Product(s): Bone marrow-derived allogeneic mesenchymal stromal cells
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Stempeucel
Highest Development Status: ApprovedProduct Type: Cell and Gene therapy
Recipient: Cipla
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 20, 2020
Details:
As per the agreement, Novumcella will initially provide regulatory support services to Stempeutics for getting approval from PMDA, Japan for conduct of bridge study in Japan for commercializing Stempeucel® product for Buerger’s Disease.
Lead Product(s): Bone marrow-derived allogeneic mesenchymal stromal cells
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Novumcella
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 28, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
